Publications by authors named "S Chraibi"

Claim this Profile
R
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.
Christophe Willekens, Alexandre Bazinet, Samy Chraibi, Alex Bataller, Justine Decroocq

Blood Cancer J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo local tolerability of a synergistic anti-tuberculosis drug combination intended for pulmonary delivery.
Faustine Ravon, Elena Menchi, Coralie Lambot, Sahar Al Kattar, Selma Chraibi

J Appl Toxicol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.
Jean Pegliasco, Pierre Hirsch, Christophe Marzac, Françoise Isnard, Jean-Côme Meniane, Samy Chraibi

Leukemia· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination of an innovative dry powder for inhalation and a standard cisplatin-based chemotherapy in view of therapeutic intensification against lung tumours.
Selma Chraibi, Rémi Rosière, Lionel Larbanoix, Pierre Gérard, Ismael Hennia

Eur J Pharm Biopharm· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancer.
S Chraibi, R Rosière, E De Prez, P Gérard, M H Antoine

Biomed Pharmacother· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis